At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
Twinrix +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 27, 2006·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating Twinrix and Decavac for HIV Infections and Hepatitis C. Completed, enrolled 29 participants across 12 sites in 2 countries.
Detailed Summary
Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The purpose of this study is to investigate the immune responses to two different vaccine formulations in HIV-infected, HCV-infected, and HCV/HIV- coinfected individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Hepatitis C
CountriesPuerto Rico, United States
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartAug 2007
Primary CompletionJul 2009
TodayJul 2026
First PostedOct 27, 2006
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.7 years ago
Interventions
Twinrixbiological
Combined hepatitis A and hepatitis B immunization
Decavacbiological
Diphtheria and tetanus toxoid vaccine